May 22th, 2023 (Shanghai) — We are glad to announce that Haru Sugino, the Head of Global Search & Evaluation of Otsuka, has been invited as a keynote speaker at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
About the speaker
Haru Sugino leads Otsuka’s Global Search & Evaluation Team based in Princeton, NJ, in Global Business Development Department. His team focuses on search & evaluation for the assets, which are in IND ready to clinical stage (P1 to NDA) for therapeutics in neuroscience (psychiatry and neurology) , Nephrology, and orphan auto-immune diseases. Dr. Haru has been working in Otsuka more than 25years starting his carrier in Otsuka as the neuroscientist by training for CNS drug discovery. He changed his role to global project coordinator when new generation antipsychotics, Brexpiprazole, successfully moved to clinical stage. In his role, he collaborated with the varieties of department including clinical/regulatory/commercial/manufacturing/head quarter, and with affiliates globally to facilitate the clinical trials, manufacturing, and commercialization. Since 2010, he is based in US office in Princeton, NJ and working for R&D and commercialization in CNS field. After Rexulti (Brexpiprazole) approved in US for dual indication, Schizophrenia and adjunctive therapy in MDD in 2015 and started the commercialization, he moved to global business development department and facilitate the search & evaluation activities. He is the member of negotiation team for the recent deals Otsuka did like Sunovion/Otsuka alliance in 2021, and licensing deal for CT-152 with Click therapeutics in 2018.
Dr. Haru hold PhD from Kyoto prefecture university of medicine for neuroscience and now EMBA candidate of Columbia business school.
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
关于药通中国-波士顿论坛
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会名称：药通中国-波士顿论坛@BIO
大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）
大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管
查看更多信息： https://biotochina.org/
MORE INFORMATION
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 